Market Research Logo

T-cell Immunotherapy: Clinical Trial Tracker

T-cell Immunotherapy: Clinical Trial Tracker

After years of research tracing back to the 18th century, a gamut of novel therapies namely, CAR-T, TCR and TIL therapies, have finally reached a point of maturity. These promising therapeutic strategies, developed under the banner of T-cell immunotherapies, are set to hit the market in the near future. T-cells, also named as the soldiers of the immune system, are featured with specificity and functionally combat infections, cancerous cells and other foreign entities. High therapeutic potential and favorable clinical outcomes outweigh the challenges such as high cost, tedious manufacturing and ethical concerns serving as the roadblocks to the progress of the therapy.

With no marketed products, this emerging field is still in its infancy. Research institutions, through investment of time, expertise and effort, have played a critical role in maturing the design and development of novel CAR-Ts, TCRs and TILs. Post the initial research, industry players have collaborated with non-industry participants to fund the clinical and commercial development of these products. Some late stage products that have emerged out of such collaborations include CTL-019 (Novartis/University of Pennsylvania/The Children’s Hospital of Philadelphia), JCAR017 (Juno Therapeutics/Seattle Children’s Hospital), KTE-C19 and HPV-16 E6 TCR (Kite Pharma/National Cancer Institute), CD19-CAR (Takara Bio / Jichi Medical University) and LN-144 (Lion Biotechnologies/National Cancer Institute).

SCOPE OF THE REPORT
The primary objective of this report is to capture details on the various clinical trials that are currently underway in the field of T-cell Immunotherapy. We have identified a number of T-cell Immunotherapy products and clinical trials that are either being conducted or planned to be conducted for each of these products. For each specific product, we have provided the following information:
1. Primary Drug
2. Highest Phase of Development
3. Developer/Licensee
4. Target Antigen

For each specific trial, we have provided the following information:
1. Indication
2. Type of Indication
3. Sponsor/Collaborator
4. Type of Sponsor
5. Trial Title
6. Trial Objective
7. Trial Phase
8. Trial Status
9. Start Date
10. End Date
11. Enrolment
12. Age Range
13. Inclusion Criteria
14. Exclusion Criteria
15. Study Design
16. Primary Endpoint
17. Secondary Endpoint
18. Treatment Arm(s)
19. Location(s)
20. Trial Results (if known)

The above information has also been presented in the form a dashboard to provide a high level quick overview of the ongoing activity in this space.

In addition to the clinical trial details, the report also provides the following:
Sales forecasts of the T-cell Immunotherapy market over the course of next fifteen years. Owing to the emerging nature of this market, we have presented three scenarios to add robustness to our market forecast. The conservative, base and optimistic scenarios represent three different tracks of industry evolution.

RESEARCH METHODOLOGY
The data presented in this report has been gathered via secondary research. The secondary sources of information include
Clinical trial registries
Clinicaltrials.gov
International Clinical Trials Registry Platform (ICTRP)
EU Clinical Trials Register (EU CTR)
Chinese Clinical Trial Register (ChiCTR)
Annual reports
Investor presentations
SEC filings
Company websites
Conference websites
Industry analysts’ views

The focus has been on capturing the details on completed and ongoing clinical trials for T-cell immunotherapy. The report also provides an in-depth analysis of the competitive landscape for both pipeline molecules and clinical trials. The analysis is solely based on our knowledge and research gathered from various secondary sources of information.

LIST OF COMPANIES
1) Adaptimmune
2) Altor Biosciences
3) Amgen
4) AstraZeneca/MedImmune
5) Atreca Therapeutics
6) Autolus
7) Baxalta
8) Beijing Doing Biomedical
9) Bellicum Pharmaceuticals
10) bluebird bio
11) Bristol Myers Squibb
12) CARsgen Therapeutics
13) Celdara Medical
14) Celgene
15) Cell Therapy Catapult
16) Cellectis
17) Cellular Biomedicine Group
18) Celyad
19) Conkwest
20) Fate Therapeutics
21) Five Prime Therapeutics
22) Formula Pharmaceuticals
23) Glaxo Smith Kline
24) iCarTAb BioMed
25) iCell Therapeutics
26) Immatics
27) Immunocore
28) Intrexon Corporation
29) Janssen Pharmaceuticals
30) Juno Therapeutics
31) JW Biotechnology
32) Key Biologics
33) Kite Pharma
34) Lion Biotechnologies
35) Lion TCR
36) MaxCyte Therapeutics
37) MediGene
38) Molmed S.p.A
39) Mustang Bio
40) Nantworks
41) Novartis
42) Oxford BioMedica
43) PersonGen Biomedicine
44) Pfizer
45) Poseida Therapeutics
46) Precision BioSciences
47) Prometheus
48) Seattle Genetics
49) Servier
50) Shanghai GeneChem
51) Shionogi
52) Sinobioway Cell Therapy
53) Sirtex Medical
54) Takara Bio
55) Theravectys
56) TILT Biotherapeutics
57) TNK Therapeutics (wholly owned subsidiary of Sorrento Therapeutics)
58) Universal Cells
59) Unum Therapeutics
60) ViroMed
61) WuXi AppTec
62) Ziopharm Oncology

LIST OF ORGANIZATIONS
1) Abramson Cancer Center of the University of Pennsylvania
2) Affiliated Hospital to Academy of Military Medical Sciences
3) Agency for Science, Technology and Research, China
4) Albert Einstein College of Medicine, Yeshiva University
5) Alex's Lemonade Stand Foundation
6) Anhui General Hospital of Armed Police Forces
7) Anhui Medical University & Hospital
8) California Institute of Technology
9) Cancer Prevention Research Institute of Texas
10) Cancer Research UK
11) Center for Cell and Gene Therapy, Baylor College of Medicine
12) Changzheng Hospital
13) Children's Mercy Hospital, Kansas City
14) Chinese PLA General Hospital
15) Christie Hospital NHS Foundation Trust
16) City of Hope Medical Center
17) Clinica Universidad de Navarra
18) CLL Global Research Foundation Alliance
19) Copenhagen University Hospital
20) Cornell Weill Medicine, Cornell University
21) Dana-Farber Cancer Institute
22) Duke University Medical Center
23) Erasmus Medical Center
24) First Hospital of Jilin University
25) Fred Hutchinson Cancer Research Center
26) Fuda Cancer Hospital
27) Fudan University Shanghai Cancer Center
28) Hadassah Medical Organization
29) Harlev Hospital
30) Hefei Binhu Hospital
31) H. Lee Moffitt Cancer Center and Research Institute
32) Hoag Memorial Hospital Presbyterian
33) Huazhong University of Science and Technology
34) James and Esther King Biomedical Research Program
35) Jichi Medical University
36) John Wayne Cancer Institute
37) Jonsson Comprehensive Cancer Center
38) Karolinska University Hospital
39) King’s College London
40) Leiden University
41) Leukaemia Lymphoma Research
42) Max Delbrück Center for Molecular Medicine in the Helmholtz Association
43) M.D. Anderson Cancer Center
44) Memorial Sloan Kettering Cancer Center
45) Mie University
46) Military Medical University
47) Nantes University & Hospital
48) National Cancer Institute
49) National Health and Medical Research Council
50) National Heart, Lung, and Blood Institute
51) National Institutes of Health
52) Peking University
53) Peter MacCallum Cancer Centre
54) RenJi Hospital
55) Roger Williams Medical Center
56) Roswell Park Cancer Institute
57) Royal Adelaide Hospital Cancer Centre
58) San Raffaele Hospital
59) Seattle Children's Hospital
60) Shanghai Jiao Tong University
61) Shanghai Tongji Hospital and University
62) Sheba Medical Center
63) Shenzhen Institute for Innovation and Translational Medicine
64) Shenzhen Second People's Hospital
65) Sidney Kimmel Comprehensive Cancer Center
66) Singapore General Hospital
67) Solving Kid’s Cancer
68) Southwest Hospital
69) St. Luke's Medical Center
70) Sun Yat-Sen University
71) Swedish Cancer Society
72) Texas Children's Hospital
73) The EVAN Foundation
74) The First People's Hospital of Hefei
75) The Methodist Hospital System
76) The Netherlands Cancer Institute
77) The Second Military Medical University
78) The Third Military Medical University
79) Tianjin Medical University Cancer Institute and Hospital
80) UNC Lineberger Comprehensive Cancer Center
81) University College London
82) University Health Network, Toronto
83) University of Colorado
84) University of Connecticut
85) University of Florida
86) University of Manchester
87) University of Maryland Greenebaum Cancer Center
88) University of Pennsylvania
89) University of Southern California
90) University of Zurich
91) Uppsala University
92) West China Hospital, Sichuan University
93) Wuhan General Hospital of Guangzhou Command
94) Xinqiao Hospital of Chongqing
95) Xuzhou Medical College
96) Zhejiang General Hospital of Armed Police
97) Zhujiang Hospital


Introduction and Pipeline Details
1. Market Overview
2. Dashboard: Pipeline and Trial Analysis
3. CAR-T Clinical Development: Trial Details
4. TCR Clinical Development: Trial Details
5. TIL Clinical Development: Trial Details
6. Market Forecast: Assumptions
7. Market Forecast, 2015-2030
8. Preclinical Development
9. Inclusion / Exclusion Criteria
10. Abbreviations
LIST OF FIGURES
Pipeline and Trial Details
Figure 1 T-cell Immunotherapy Products in Clinical Development: Distribution by Type of Therapy
Figure 2 T-cell Immunotherapy Trials in Clinical Development: Distribution by Type of Therapy
Figure 3 T-cell Immunotherapy Products in Clinical Development: Distribution by Phase of Development
Figure 4 T-cell Immunotherapy Products in Clinical Development: Distribution by Phase of Development and Type of Therapy
Figure 5 T-cell Immunotherapy Products in Clinical Development: Distribution by Therapeutic Area
Figure 6 T-cell Immunotherapy Products in Clinical Development: Distribution by Therapeutic Area and Type of Therapy
Figure 7 T-cell Immunotherapy Products in Clinical Development: Distribution by Target in the CAR-T Market
Figure 8 T-cell Immunotherapy Products in Clinical Development: Distribution by Targets in the TCR Market
Figure 9 T-cell Immunotherapy Products in Clinical Development: Distribution by Industrial Developers for CAR-T Therapy
Figure 10 T-cell Immunotherapy Products in Clinical Development: Distribution by Industrial Developers for TCR Therapy
Figure 11 T-cell Immunotherapy Trials in Clinical Development: Distribution by Phase of Development
Figure 12 T-cell Immunotherapy Trials in Clinical Development: Distribution by Phase of Development and Type of Therapy
Figure 13 T-cell Immunotherapy Trials in Clinical Development: Distribution by Therapeutic Area
Figure 14 T-cell Immunotherapy Trials in Clinical Development: Distribution by Therapeutic Area and Type of Therapy
Figure 15 T-cell Immunotherapy Trials in Clinical Development: Distribution by Trial Status
Figure 16 T-cell Immunotherapy Trials in Clinical Development: Distribution by Trial Status and Type of Therapy
Figure 17 T-cell Immunotherapy Trials in Clinical Development: Distribution by Sponsorship
Figure 18 T-cell Immunotherapy Trials in Clinical Development: Distribution by Sponsorship and Type of Therapy
Figure 19 T-cell Immunotherapy Trials in Clinical Development: Distribution by Region
Figure 20 T-cell Immunotherapy Trials in Clinical Development: Distribution by Region and Type of Therapy
Figure 21 T-cell Immunotherapy Trials in Clinical Development: Distribution by G7 Countries
Figure 22 T-cell Immunotherapy Trials in Clinical Development: Distribution by G7 Countries and Type of Therapy
Market Forecast Analysis
Figure A T-cell Immunotherapy Market Forecast, 2015-2030
Figure B T-cell Immunotherapy Market, Share of Sub-segments: Base Scenario 2020, 2025 and 2030 (USD Million)
LIST OF TABLES
Pipeline Details
Table 1 CART Clinical Development: Pipeline Details
Table 2 TCR Clinical Development: Pipeline Details
Table 3 TIL Clinical Development: Pipeline Details
Table 4 Preclinical Development
Market Forecast Analysis
Table A Market Forecast: Assumptions

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report